Cost-effectiveness analysis of patent foramen ovale closure versus medical therapy alone after cryptogenic stroke

Yoko Shijoh1*, Shota Saito2, Zhehao Dai3,4, Sachiko Ohde1

1 Graduate School of Public Health St. Luke’s International University, Chuo-City, Tokyo, Japan, 2 Niigata University Graduate School of Medical and Dental Sciences, Niigata-City, Niigata, Japan, 3 Department of Cardiovascular Medicine, The University of Tokyo Hospital, Bunkyo-City, Tokyo, Japan, 4 Department of Cardiovascular Medicine, St. Luke’s International Hospital, Chuo-City, Tokyo, Japan

* 19mp214@slcn.ac.jp

Abstract

Background
Closure of a patent foramen ovale reduces the risk of recurrent stroke compared with medical therapy alone in young patients with cryptogenic strokes revealed by randomized control trials. Some cost-effectiveness analyses outside Japan have shown that patent foramen ovale closure is cost-effective, but no studies have examined cost-effectiveness in Japan. The objective of this study is to assess cost-effectiveness, from the perspective of a Japanese healthcare payer, of patent foramen ovale closure versus medical therapy alone for patients with patent foramen ovale related to cryptogenic strokes.

Methods
A cost-effectiveness study was conducted by developing a decision tree and a Markov model. Probabilities and a 5.9-year time horizon followed the RESPECT study. Utilities and costs were based upon published studies and assumptions. All assumptions were assessed by experts, including a cardiologist and a statistical expert. The target population comprised patients with cryptogenic stroke and patent foramen ovale, aged 60 years or younger. The model was discounted at 2.0% and its cycle was one month. A willingness-to-pay threshold is set at $50,000 / quality-adjusted life years (QALYs). Incremental cost-effectiveness ratio was evaluated. Then one-way sensitivity analyses as deterministic sensitivity analysis, and probabilistic sensitivity analyses were performed to assess data robustness.

Results
Incremental quality-adjusted life years, incremental costs, and incremental cost-effectiveness ratio were 0.464, $13,562, and $29,208 per QALY gained, respectively. One-way sensitivity analysis showed that the stable state utility score difference between patent foramen ovale closure and medical therapy had the largest impact on incremental cost-effectiveness ratio. Patent foramen ovale closure is cost-effective at a stable state utility score difference
study. The authors would like to declare the following patents/patent applications associated with this research: aspirin and rivaroxaban. There are no patent numbers to declare.

of >0.051, compared with medical therapy. Probabilistic sensitivity analyses demonstrated that patent foramen ovale closure was 50.3% cost-effective.

Conclusions
Patent foramen ovale closure was cost-effective compared with medical therapy for Japanese patients with cryptogenic stroke who were ≤60 years.

Introduction
Patent foramen ovale (PFO) is an opening in the septum between the right and left atria that failed to close at birth. Relative to the total number of general autopsy findings, the prevalence of PFO is reportedly 26% [1]. Under certain hemodynamic conditions, such a PFO can be forced open by a pressure gradient that favors right-to-left shunting, thereby enabling blood and bloodborne substances to pass from the venous to the arterial circulation [2]. This is the mechanism whereby PFO is associated with paradoxical embolism, which is the most common cause of cryptogenic stroke in young adults [3].

Approximately 25% of cerebral infarctions are of unknown cause, but some are thought to be due to thrombi from the right heart system that entered the left heart system through right-to-left shunts, such as a PFO. These are called paradoxical embolisms. However, thrombi in the right heart system are often not detected in cases of cerebral infarction with PFO, and no treatment showing clear effectiveness has been established for prevention of recurrent stroke in cases in which aspirin is commonly used [4]. Possible treatments to prevent recurrent stroke in cryptogenic stroke patients with a PFO include medical treatment with antiplatelet agents or anticoagulants, percutaneous PFO closure, and surgical PFO closure.

Recently, several randomized controlled trials showed that percutaneous transcatheter closure reduces the risk of recurrent stroke compared with medical therapy alone, among relatively young patients with cryptogenic stroke complicated by a PFO [5–7]. The Japanese government approved a percutaneous transcatheter closure device, AMPLATZER PFO Occluder, and its procedure in 2019 for secondary prevention of ischemic stroke in patients ≤60 years who had a cryptogenic stroke that was probably attributable to a PFO. Until 2020, AMPLATZER PFO Occluder was the only device approved in Japan for PFO closure. Soon after the government approved the device and procedure, the Japan Stroke Society, the Japanese Circulation Society, and the Japan Cardiovascular Intervention Treatment Society released guidelines for percutaneous PFO closure for cryptogenic stroke [4]. These guidelines were based upon evidence from three randomized control trials (RCTs) in 2017: RESPECT [5], REDUCE [6] and CLOSE [7], which focused on efficacy and safety with an appropriate patient background. The guidelines raised the clinical issue of postoperative atrial fibrillation rate, which was higher in the PFO closure group than in a non-closure group in a meta-analysis that included the three aforementioned RCTs [8–10].

Reduction of the recurrent stroke rate is important, not only from a clinical perspective, but also from a health economic perspective. Some cost-effectiveness analyses outside Japan have compared PFO closure and medical therapy alone for cryptogenic stroke patients and have shown that PFO closure is cost-effective. [11–16]. However, there have been no cost-effectiveness analyses in Japan and such analyses, which include cost information, utility scores, and a lifetable would be more convincing than cost-effectiveness analyses done outside Japan. Therefore, our objective was to assess the cost-effectiveness, from a Japanese healthcare payer perspective, of PFO closure with AMPLATZER PFO Occluder for risk reduction of recurrent
stroke in patients with cryptogenic stroke that was probably attributable to a PFO, compared to medical therapy alone.

**Method**

**Model overview**

We developed a decision tree and Markov model to assess the cost-effectiveness of PFO closure compared with medical therapy alone (Figs 1 and 2). For the Markov model, we proposed a model consisting of four health states: stable after cryptogenic stroke, post-minor recurrent stroke, post-moderate recurrent stroke, and death (Fig 1). We used a modified Rankin Scale (mRS) to categorize post-minor stroke as mRS 0 to 2 and post-moderate recurrent stroke as mRS 3 to 5. The time horizon was derived from the RESPECT study median follow-up period, which was 5.9 years [5]. The model cycle was one month. Quality of life (QOL) scores for each condition were calculated, and to calculate an incremental cost-effectiveness ratio (ICER), the incremental cost increase per PFO closure was divided by the quality-adjusted life years (QALYs) gained by the closure. $50,000 per QALY was determined as the cost-effectiveness willingness-to-pay that the Japanese government sets as the ICER threshold in the cost-effectiveness evaluation system. We conducted one-way sensitivity analyses with varied key assumptions to assess robustness. The model was discounted at 2.0%, which is a basic discount rate in the guidelines for preparing cost-effectiveness evaluations for the central social insurance medical council in Japan. All analyses were performed using TreeAge Pro software.

**Patients**

The target population included cryptogenic stroke patients who had a PFO, aged ≤ 60 years, based on the indication for AMPLATZER™ PFO Occluder in Japan. The Japanese government

---

**Fig 1. Decision tree.** A decision tree shows that a patient who had a PFO enters this model after a cryptogenic stroke and is assigned either a PFO closure or medical treatment. PFO closure has three possible outcomes: complication, non-complication, or death. Abbreviations. PFO, patent foramen ovale.

https://doi.org/10.1371/journal.pone.0268690.g001
approved AMPLATZER™ PFO Occluder based on the RESPECT study results of “rates of 0.58 events per 100 patient-years and 1.07 events per 100 patient-years, respectively (hazard ratio with PFO closure vs. medical therapy, 0.55; 95% confidence interval [CI], 0.31 to 0.99; p = 0.046 by the log-rank test).” Thus, patients in the model represent the RESPECT study, a multi-center, randomized, open-label, controlled clinical trial with blinded adjudication of end point events [5]. In the RESPECT study, 980 patients (mean age, 45.9 years) were included from 69 sites. Patients had had a cryptogenic ischemic stroke, were 18 to 60 years of age, had a PFO that was confirmed by transesophageal echocardiography, and were followed for a median of 5.9 years [5]. Patients in the PFO closure group underwent a procedure in which the Amplatzer PFO Occluder was inserted with fluoroscopic and echocardiographic guidance. After the procedure, patients in the PFO closure group received aspirin plus clopidogrel daily for 1 month, followed by aspirin monotherapy for 5 months. Subsequently, antithrombotic therapy after 6 months was at the discretion of the site investigator. In the medical-therapy group, four medical therapies (aspirin, warfarin, clopidogrel, and aspirin combined with extended-release dipyridamole) were allowed throughout the trial and the majority received aspirin alone (54%) [5].

Probabilities and utilities

Probabilities for each outcome obtained from published literature are shown in Table 1. There were no available Japanese cohort data for PFO closure thus probabilities for recurrent ischemic stroke were estimated on a monthly cycle based on the RESPECT study primary endpoint. We assumed that the recurrent ischemic stroke rate persists during the simulation. In the decision tree, we set atrial fibrillation and flutter as procedural complications, because calculation of low-incidence, serious adverse events (SAEs) is impractical and should only address clinically problematic SAEs. This conclusion was based on guidance from the Japan Stroke Society, the Japanese Circulation Society, and the Japan Cardiovascular Intervention Treatment Society for percutaneous patent foramen ovale closure for latent cerebral infarction. This statement argued that meta-analysis clarified the effectiveness of this treatment, despite the increased risk of postoperative atrial fibrillation [8–10].

We assumed that the utility score of each health status remained unchanged until the health status changed. The previous assumption of a stable utility score was used from the cost-effectiveness analysis, which was 0.88 for closure-stable utility and 0.8 for medical therapy-stable
This assumption was based on expert opinion and some previous studies showing a positive impact of the closure procedure on quality of life. Mirzada N [17] explained that the prospect of effective secondary prevention of ischemic recurrences could certainly contribute to better physical, mental, and social functioning in patients who undergo PFO closure. Results reported by Evola S [18] indicated a reasonable association with improvement of migraines, due to a reduction in the frequency and severity of migraine attacks. Lelakowska M [19] also reported that the utility score value of the SF-36 total score was markedly higher 6 months after PFO closure compared with pre-PFO closure.
Based on previous mortality rate reports on cryptogenic stroke patients [20], we used average values of mortality indices categorized into three spans: post-stroke mortality within 1 year, post-stroke mortality within 5 years, and post-stroke mortality within 10 years. Recurrent clinical ischemic stroke was assumed to be 68% for post-minor strokes and 32% for post-moderate strokes, assumptions supported by Grau AJ [21].

We set atrial fibrillation utility using a previous study [22], and minor stroke utility and moderate utility using a Japanese study calculated with the modified Rankin Scale and EQ-5D Japanese version [23].

**Cost and lifetime table**

Our analysis was conducted from a healthcare payer perspective. We estimated direct medical costs based on Japanese price lists [24] and the standardized frequency of each intervention for procedure costs, medication costs, and follow-up costs. All costs were converted in international Dollars using 0.88 dollar for 100 yen as the Dollar to Yen exchange rate (USD JPY) as of 30 Nov 2021. Costs for each outcome was shown in Table 1.

Treatment costs for acute clinical ischemic stroke and post-clinical ischemic stroke were obtained from previous studies in Japan [23, 25]. We used the 2018 Japanese lifetime table to obtain the annual probability of natural death [26].

**Sensitivity analysis**

One-way sensitivity and probabilistic sensitivity analyses evaluated the impact of assumptions shown by the sensitivity analysis range in Table 1. Lifetime horizon was set as the upper value of time to follow-up, which was 38.3 years, calculated as 84.2 (average life expectancy in Japan) minus 45.9 (mean age of patients in the RESPECT study [5]). We set 5.9 years as the lower value of the time horizon, which is the base case value derived from the RESPECT study [5] median follow-up period. The PFO closure risk ratio of recurrent stroke was obtained from the RESPECT study [5] and we used 95% confidence intervals of the PFO closure risk ratio of recurrent stroke (0.31–0.999) as the lower and upper range. In the RESPECT study [5], the rate of atrial fibrillation or flutter did not differ significantly between the PFO closure and medical therapy groups. The risk ratio was 1.69 and 95% confidence interval was 0.50 to 5.73. We used 1.69 for the base value and 0.50 for the lower value. However, the meta-analysis found that “the rate of newly detected atrial fibrillation in the PFO closure plus medical therapy group and the medical therapy alone group were 4.3% and 0.7%, respectively, which shows that PFO closure plus medical therapy significantly increased the risk of newly detected atrial fibrillation by more than 4 times compared with medical therapy alone (RR 4.69, 95% CI 2.17 to 10.12)” [8]. We thus used the upper 95% confidence interval limits of newly detected atrial fibrillation in the meta-analysis as the upper range of atrial fibrillation or flutter rate hazard ratio between closure and non-closure. Other probability scores were set at ±10%, based on expert opinion.

Previous cost-effectiveness studies have shown that stable state utility scores between closure and medical therapy have the widest range for ICERs [11, 13–15]. No studies report a difference in stable utility scores between closure and medical therapy, and stable utility scores were thus all based on assumption. To clarify the threshold of a stable utility score difference for cost-effectiveness, we set a lower stable utility score difference of 0 and an upper stable utility score difference of 0.08, which was the baseline. Other utility scores and costs were set at ±10% and ±20%, respectively, based on expert opinion. Costs for each upper and lower value were shown in Table 1.
Cost-effectiveness acceptability curves were determined for the probabilistic sensitivity analysis on the parameter uncertainty at a 5.9-year time horizon. Triangular or gamma distributions were chosen for each parameter (Table 1) and the model was run 10000 times.

Results

Base case analysis

According to the analysis results, PFO closure yielded 4.849 QALYs at a cost of $20,924 and medical therapy yielded 4.385 QALYs at a cost of $7,361 over a 5.9-year time horizon (Table 2). ICER of PFO closure compared with medical therapy was estimated at $29,208 per QALY gained; therefore, PFO closure is cost-effective compared with medical therapy, based on the ICER threshold set by the Japanese government in the cost-effectiveness evaluation system.

Sensitivity analysis

Results of one-way sensitivity analysis indicated that the stable state utility score difference between closure and medical therapy had the largest impact on the ICER (Fig 3). With a lower value estimate of 0.00, ICER in the sensitivity analysis was $407,800 per QALY gained, exceeding acceptable limits of cost-effectiveness. To be cost-effective, thresholds of the stable state utility score difference between closure and medical therapy should be 0.051 (Fig 4).

The second largest impact on ICER was the time horizon. PFO closure at the lifetime horizon, which was 38.3 years setting as the upper value of time to follow-up, changed to a dominant economic strategy, resulting in cost reduction and gain in QALY with a base case value having a stable state utility score difference compared with medical therapy (Fig 5).

Probabilistic sensitivity analyses demonstrated that PFO closure was 50.3% cost-effective with a willingness-to-pay threshold of $50,000 /QALY at a 5.9-year time horizon (Fig 6). This result of this probabilistic sensitivity analysis means that PFO closure may be cost-effective, but there is still roughly a 50% chance of its not being cost-effective.

Discussion

We evaluated the cost-effectiveness in Japan of PFO closure compared to medical therapy after cryptogenic stroke. The analysis revealed that PFO closure is cost-effective in the base case model, resulting in an ICER of $29,208 per QALY gained. Previous cost-effectiveness analyses outside Japan also revealed that PFO closure is cost-effective compared with medical therapy for cryptogenic stroke patients [11–16]. A cost-effectiveness study in the U.S. [11] showed that PFO closure achieved an ICER of $21,049 at five years. In a U.K. study [15], ICER was reportedly £20,951 at four years. Both results are consistent with the Japanese situation. However, one-way sensitivity analysis showed that the stable state utility score difference between PFO closure and medical therapy had the largest impact on ICER. In other words, a stable state utility score difference below 0.051 rendered a result that was not cost-effective. This was the most important finding of this study because we assumed a base case utility score.

Table 2. Base case cost-effectiveness analysis.

| Treatment | Total cost | Incremental Cost | Total QALY | Incremental Effectiveness | ICER |
|-----------|------------|-----------------|------------|--------------------------|------|
| Medical Therapy | $7,361 |                 | 4.385 |                      |      |
| Closure | $20,924 | $13,562 | 4.849 | 0.464 | 29,208 |

Abbreviations. QALY, quality-adjusted life-years; ICER, incremental cost-effectiveness ratio.

https://doi.org/10.1371/journal.pone.0268690.t002
Sensitivity analysis also supports the result that PFO closure was only 50.3% cost-effective with a willingness-to-pay threshold of $50,000/QALY at a 5.9-year time horizon.

However, this study has some limitations. Main probabilities such as closure risk ratio of recurrent stroke and PFO closure atrial fibrillation or flutter HR came from studies outside Japan, which could be a potential bias so that Japanese Real-world evidence is needed.

Assumptions of previous cost-effectiveness studies were based on expert opinions and some published literature, which indicated that PFO closure not only reduces recurrent stroke, but also patient anxiety about recurrent stroke. Study authors further indicated that PFO

![Fig 3. One-way sensitivity analysis of PFO closure VS medical therapy. The impact of parameter variation using a willingness-to-pay threshold of $50,000/QALY. The hatched bars and black bars show the upper (high estimate) and lower values of the parameter, respectively. Bars are aligned in order of impact from largest to smallest. Abbreviations. PFO, patent foramen ovale; mRS, modified Rankin Scale; DOAC, novel direct oral anticoagulants.](https://doi.org/10.1371/journal.pone.0268690.g003)
closure also reduces PFO-related migraine so that such reduction may improve the stable utility score, but we cannot be certain whether the utility score difference between PFO closure and medical therapy exceeds 0.051 without a reliable utility score for patients who have backgrounds similar to those in the RESPECT study. In addition, Japanese utility score evidence is important because of the difference in life expectancy and medical care systems in other countries. Hence, the Japanese stable utility score after PFO closure and medical therapy among patients with cryptogenic stroke and PFO aged \( \leq 60 \) years needs to be determined through further studies. With new utility score evidence, Japanese criteria for PFO closure should be changed by releasing the quality indicator score to show that patient quality of life improves.

The goal of the basic act on stroke and cardiovascular disease countermeasures of 2018 is to promote healthy life expectancy. Our results may promote a cost-effective, healthy life expectancy by reducing recurrent ischemic strokes, which remain the leading cause of long-term disability. However, most reports on utility scores of stroke patients are from Europe and the United States, and very few studies with cases exist in Japan. When evaluating utility scores, it is necessary to use a reliable, validated measurement scale, but there are few such scales at present. Especially for new procedures or treatments, such as PFO closure, there is no evidence that shows the exact utility score after releasing RCTs all over the world. Without reliable utility scores, cost-effectiveness studies will always lack core information and can only offer hypotheses regarding economic impact.

In April 2019, the Ministry of Health Labour and Welfare (MHLW) of Japan introduced a cost-effectiveness evaluation system. The aim of the system is to utilize results of cost-
Fig 5. One-way sensitivity analysis: Time horizon closure vs. medical therapy. Time horizon closure vs. medical therapy, which is the second largest impact of parameter variation, is shown with ICER. Abbreviations. ICER, incremental cost-effectiveness ratio.

https://doi.org/10.1371/journal.pone.0268690.g005

Fig 6. Cost-effectiveness acceptability curves. Willingness-to-pay ($) is shown with percent cost-effectiveness. The dashed line is a willingness-to-pay threshold (WTP) of $50,000/QALY and the percent cost effectiveness is 50.3% at a WTP of $50,000/QALY. Abbreviations. WTP, Willingness-to-pay.

https://doi.org/10.1371/journal.pone.0268690.g006
effectiveness evaluations that will not be used for reimbursement decisions, but for post-listing price adjustments [28]. Thus, utility score research should be performed using national grants for accurate evaluation of cost-effectiveness studies.

With an accurate utility score, PFO closure become a new component of a cardiovascular disease prevention strategy for the Japanese population. Our cost-effectiveness analysis of PFO closure supports this conclusion and can serve as a reference to consider whether political resources of the basic act on stroke and cardiovascular disease countermeasures should be allocated.

**Conclusion**

From a healthcare payer perspective, PFO closure is cost-effective compared with medical therapy in Japanese patients ≤60 years with cryptogenic strokes that are probably attributable to a PFO.

**Supporting information**

S1 Data. (XLSX)

**Author Contributions**

**Conceptualization:** Yoko Shijoh, Shota Saito, Zhehao Dai, Sachiko Ohde.

**Data curation:** Yoko Shijoh, Shota Saito, Zhehao Dai, Sachiko Ohde.

**Formal analysis:** Yoko Shijoh, Shota Saito, Zhehao Dai, Sachiko Ohde.

**Investigation:** Yoko Shijoh, Shota Saito, Zhehao Dai, Sachiko Ohde.

**Methodology:** Yoko Shijoh, Shota Saito, Zhehao Dai, Sachiko Ohde.

**Project administration:** Yoko Shijoh.

**Supervision:** Sachiko Ohde.

**Validation:** Yoko Shijoh, Shota Saito.

**Visualization:** Yoko Shijoh, Shota Saito.

**Writing – original draft:** Yoko Shijoh.

**Writing – review & editing:** Shota Saito, Zhehao Dai, Sachiko Ohde.

**References**

1. Homma S, Sacco RL. Patent foramen ovale and stroke. Circulation. 2005; 112(7):1063–72. https://doi.org/10.1161/CIRCULATIONAHA.104.524371 PMID: 16103257

2. Calvert PA, Rana BS, Kydd AC, Shapiro LM. Patent foramen ovale: Anatomy, outcomes, and closure. Nat Rev Cardiol. 2011; 8(3):148–60. https://doi.org/10.1038/nrcardio.2010.224 PMID: 21283148

3. Sastry S, Riding G, Morris J, Taberner D, Cherry N, Heagerty A, et al. Young Adult Myocardial Infarction and Ischemic Stroke. The Role of Paradoxical Embolism and Thrombophilia (The YAMIS Study). J Am Coll Cardiol. 2006; 48(4):686–91. https://doi.org/10.1016/j.jacc.2006.02.074 PMID: 16990453

4. Japan Stroke Society, Japanese Circulation Society and JCITS. Guidance of patent foramen ovale closure for cryptogenic ischemic stroke (in Japanese) [Internet]. 2019 [cited 2021 Aug 2]. Available from: https://www.jssts.gr.jp/img/tebiki_senisuisou.pdf

5. Saver JL, Carroll JD, Thaler DE, Smalling RW, MacDonald LA, Marks DS, et al. Long-Term Outcomes of Patent Foramen Ovale Closure or Medical Therapy after Stroke. N Engl J Med. 2017; 377(11):1022–32. https://doi.org/10.1056/NEJMoat1610057 PMID: 28902590
6. Sendergaard L, Kasner SE, Rhodes JF, Andersen HK, Iversen HK, Nielsen-Kudsk JE, et al. Patent Foramen Ovale Closure or Antiplatelet Therapy for Cryptogenic Stroke. N Engl J Med. 2017; 377(11):1033–42. https://doi.org/10.1056/NEJMa1707404 PMID: 28902580

7. Mas J-L, Derumeaux G, Guillou B, Massardier E, Hosseini H, Mechtouff L, et al. Patent Foramen Ovale Closure or Anticoagulation vs. Antiplatelets after Stroke. N Engl J Med. 2017; 377(11):1011–21. https://doi.org/10.1056/NEJMo1705915 PMID: 28902593

8. Ando T, Holmes AA, Pahuja M, Javed A, Briasoulis A, Tellia T, et al. Meta-Analysis Comparing Patent Foramen Ovale Closure Versus Medical Therapy to Prevent Recurrent Cryptogenic Stroke. Am J Cardiol [Internet]. 2018; 121(5):649–55. Available from: https://doi.org/10.1016/j.amjcard.2017.11.037 PMID: 29306484

9. Vaduganathan M, Qamar A, Gupta A, Bajaj N, Golwala HB, Pandey A, et al. Patent Foramen Ovale Closure for Secondary Prevention of Cryptogenic Stroke: Updated Meta-Analysis of Randomized Clinical Trials. Am J Med [Internet]. 2018; 131(5):575–7. Available from: https://doi.org/10.1016/j.amjmed.2017.11.027 PMID: 29229471

10. Mojadidi MK, Elgendy AY, Elgendy IY, Mahmoud AN, Elbadawi A, Eshtehardi P, et al. Transcatheter Patent Foramen Ovale Closure After Cryptogenic Stroke: An Updated Meta-Analysis of Randomized Trials. JACC Cardiovasc Interv. 2017; 10(21):2228–30. https://doi.org/10.1016/j.jcin.2017.09.002 PMID: 29122137

11. Volpi JJ, Ridge JR, Nakum M, Rhodes JF, Sendergaard L, Kasner SE. Cost-effectiveness of percutaneous closure of a patent foramen ovale compared with medical management in patients with a cryptogenic stroke: from the US payer perspective. J Med Econ [Internet]. 2018; 22(9):883–90. Available from: https://doi.org/10.1080/13696998.2019.1611587 PMID: 31025589

12. Leppert MH, Poisson SN, Carroll JD, Thaler DE, Kim CH, Hartaigh B, Evans RM, et al. Cost-effectiveness of patent foramen ovale closure versus medical therapy for secondary stroke prevention. Stroke. 2018; 49(6):1443–50. https://doi.org/10.1161/STROKEAHA.117.020322 PMID: 29720435

13. Hillick-Smith D, Turner M, Shaw L, Nakum M, Hartaigh B, Evans RM, et al. Evaluating the cost-effectiveness of percutaneous closure of a patent foramen ovale versus medical management in patients with a cryptogenic stroke: from the UK payer perspective. J Med Econ [Internet]. 2019; 22(2):131–9. Available from: https://doi.org/10.1080/13696998.2018.1546445 PMID: 30424680

14. Pickett CA, Villines TC, Resar JR, Hulten EA. Cost effectiveness and clinical efficacy of patent foramen ovale closure as compared to medical therapy in cryptogenic stroke patients: A detailed cost analysis and meta-analysis of randomized controlled trials. Int J Cardiol [Internet]. 2018; 273:74–9. Available from: https://doi.org/10.1016/j.ijcard.2018.07.099 PMID: 30119914

15. Tirschwell DL, Turner M, Thaler D, Choulerton J, Marks D, Carroll J, et al. Cost-effectiveness of percutaneous patent foramen ovale closure as secondary stroke prevention. J Med Econ [Internet]. 2018; 21(7):656–65. Available from: https://doi.org/10.1080/13696998.2018.1456445 PMID: 29564942

16. Pickett CA, Villines TC, Ferguson MA, Hulten EA. Cost effectiveness of percutaneous closure versus medical therapy for cryptogenic stroke in patients with a patent foramen ovale. Am J Cardiol [Internet]. 2014; 114(10):1584–9. Available from: https://doi.org/10.1016/j.amjcard.2014.08.027 PMID: 25248812

17. Mirzada N, Ladenvall P, Hansson PO, Eriksson P, Taft C, Dellborg M. Quality of life after percutaneous closure of patent foramen ovale in patients after cryptogenic stroke compared to a normative sample. Int J Cardiol [Internet]. 2018; 257:46–9. Available from: https://doi.org/10.1016/j.ijcard.2018.01.120 PMID: 29422265

18. Evola S, Kauoro BAW, Trovato RL, Alioto L, D’Amico G, Fonte G, et al. The percutaneous closure of patent foramen ovale (PFO): Impact on the quality of life. Int J Cardiol [Internet]. 2013; 168(2):1622–3. Available from: https://doi.org/10.1016/j.ijcard.2013.01.015 PMID: 23398832

19. Lelakowska M, Matusik PT, Podolec PS, Olszowska M, Nessler JM, Podolec N, et al. Transcatheter closure of atrial septal communication: Impact on quality of life in mid-term follow-up. Adv Clin Exp Med. 2019; 28(8):1079–85. https://doi.org/10.17219/acem/102440 PMID: 31237120

20. Li L, Yiu GS, Geraghty OC, Schulz UG, Kuker W, Mehta Z, et al. Incidence, outcome, risk factors, and long-term prognosis of cryptogenic transient ischaemic attack and ischaemic stroke: A population-based study. Lancet Neurol [Internet]. 2015; 14(9):903–13. Available from: http://dx.doi.org/10.1016/S1474-4422(15)00132-5

21. Grau AJ, Weimar C, Buggle F, Heinrich A, Goertler M, Neumaier S, et al. The German Stroke Data Bank. Stroke. 2001; 32(11):2559–66.

22. Reynolds MR, Zimetbaum P, Josephson ME, Ellis E, Danilov T, Cohen DJ. Cost-effectiveness of radiofrequency catheter ablation compared with antiarrhythmic drug therapy for paroxysmal atrial fibrillation. Circ Arrhythmia Electrophysiol. 2009; 2(4):362–9. https://doi.org/10.1161/CIRCEP.108.837294 PMID: 19808491
23. Hattori N, Hirayama T, Katayama Y. Medical care for chronic-phase stroke in Japan. Neurol Med Chir (Tokyo). 2012; 52(4):175–80. https://doi.org/10.2176/nmc.52.175 PMID: 22522326
24. Igaku-tsushinsha. Medical Treatment Fee Point April 2020. 2020.
25. Kamae I, Hashimoto Y, Koretsune Y, Tanahashi N, Murata T, Phatak H, et al. Cost-effectiveness Analysis of Apixaban against Warfarin for Stroke Prevention in Patients with Nonvalvular Atrial Fibrillation in Japan. Clin Ther [Internet]. 2015; 37(12):2837–51. Available from: https://doi.org/10.1016/j.clinthera.2015.10.007 PMID: 26608819
26. Ministry of Health, Labour and W. Life Tables [Internet]. 2018 [cited 2021 Aug 2]. Available from: https://www.mhlw.go.jp/toukei/saikin/hou/saikou/geppo/nengai18/index.html
27. WHO. WORLD HEALTH STATISTICS 2020 MONITORING HEALTH FOR THE SDGs [Internet]. World Health Organization. 2020 [cited 2021 Aug 2]. p. 1–77. Available from: https://www.who.int/publications/i/item/9789240005105
28. Ministry of Health Labour and Welfare. Cost-effectiveness evaluation system in Japan [Internet]. 2019 [cited 2021 Aug 2]. Available from: https://www.mhlw.go.jp/content/12404000/000480976.pdf